The effect of dietary nitrate supplementation on blood pressure and exercise capacity in people with COPD

Oral Nitrate supplementation and Blood pressure in COPD – a randomised clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN47839214

Enrollment

Registered

2019-11-01

Start date

2019-12-01

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable COPD Respiratory

Interventions

Allocation will be by computer-generated randomisation. Active: 70 ml Beet It Stamina shot from James White Ltd (6.5 mmol Nitrate) once daily for three months Placebo: 70 ml matched placebo shot with

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult patients (>21 years) with stable COPD GOLD I-IV 2. Established on stable pharmacotherapy for COPD 3. Systolic blood pressure >130 mmHg

Exclusion criteria

Exclusion criteria: 1. Unable to provide informed consent 2. AECOPD in the preceding month 3. Significant comorbidity limiting exercise tolerance 4. Significant comorbidity limiting life expectancy 5. Significant renal impairment (estimated glomerular filtration rate (eGFR) 3 blood pressure lowering medications 7. Change in medication in the previous month 8. Oral nitrate medication 9. Current (in the last month) use of Beet Shots

Design outcomes

Primary

Measure	Time frame
Home-monitored blood pressure measured using ambulatory blood pressure monitoring at baseline and 3 months	—

Secondary

Measure	Time frame
Secondary endpoints: 1. Exercise capacity measured using 6-minute walk test distance at baseline and 3 months 2. Health-related quality of life (HRQoL) assessed using the CAT score at baseline and 3 months Exploratory endpoints measured at baseline and 3 months: 1. Endothelial function assessed using the Endopat score 2. Cardiac strain measured using Blood Brain Natriuretic Peptide levels (BNP) 3. Platelet activation measured using blood platelet-monocyte aggregates 4. Nitric oxide synthase activity assessed using plasma concentration of arginine/asymmetric dimethylarginine (ADMA) 5. Breath nitric oxide measured using fractional exhaled NO (FeNO) 6. Adequacy of supplementation measured using blood nitrate and nitrite levels 7. Nitrate metabolising oral bacteria measured using oral microbiome sampling	—

Measure

Time frame

Secondary endpoints: 1. Exercise capacity measured using 6-minute walk test distance at baseline and 3 months 2. Health-related quality of life (HRQoL) assessed using the CAT score at baseline and 3 months Exploratory endpoints measured at baseline and 3 months: 1. Endothelial function assessed using the Endopat score 2. Cardiac strain measured using Blood Brain Natriuretic Peptide levels (BNP) 3. Platelet activation measured using blood platelet-monocyte aggregates 4. Nitric oxide synthase activity assessed using plasma concentration of arginine/asymmetric dimethylarginine (ADMA) 5. Breath nitric oxide measured using fractional exhaled NO (FeNO) 6. Adequacy of supplementation measured using blood nitrate and nitrite levels 7. Nitrate metabolising oral bacteria measured using oral microbiome sampling

—

Countries

England, United Kingdom

Contacts

Public ContactAli Alasmari

a.alasmari18@imperial.ac.uk+44 (0)2073518029

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026